BioSmart Co.Ltd (038460) — Cash Flow-to-Debt Ratio
BioSmart Co.Ltd (038460) has a Cash Flow-to-Debt Ratio of 0.07x as of September 2025, meaning its operating cash flow of ₩7.59 Billion could theoretically repay 0% of its total liabilities (₩109.14 Billion) in one year. See BioSmart Co.Ltd (038460) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BioSmart Co.Ltd Cash Flow-to-Debt Ratio (2010–2024)
Historical debt coverage capacity for BioSmart Co.Ltd across 14 annual periods. Also explore 038460 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for BioSmart Co.Ltd (2010–2024)
Year-by-year debt coverage analysis for BioSmart Co.Ltd. For market capitalisation and broader financial context, see BioSmart Co.Ltd market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.03x | ₩3.80 Billion | ₩133.36 Billion | ▲ +238.3% |
| 2023 | 0.01x | ₩1.17 Billion | ₩138.43 Billion | ▼ -78.8% |
| 2022 | 0.04x | ₩5.59 Billion | ₩140.46 Billion | ▲ +319.3% |
| 2021 | 0.01x | ₩1.20 Billion | ₩126.75 Billion | ▲ +109.1% |
| 2020 | -0.10x | ₩-7.49 Billion | ₩71.45 Billion | ▼ -345.5% |
| 2019 | -0.02x | ₩-1.84 Billion | ₩78.08 Billion | ▼ -124.6% |
| 2018 | 0.10x | ₩5.81 Billion | ₩60.89 Billion | ▲ +360.6% |
| 2017 | -0.04x | ₩-1.76 Billion | ₩47.97 Billion | ▲ +38.0% |
| 2016 | -0.06x | ₩-3.13 Billion | ₩52.97 Billion | ▼ -82.7% |
| 2015 | -0.03x | ₩-509.17 Million | ₩15.76 Billion | ▼ -142.8% |
| 2014 | 0.08x | ₩1.31 Billion | ₩17.30 Billion | ▼ -49.8% |
| 2013 | 0.15x | ₩3.85 Billion | ₩25.58 Billion | ▼ -46.4% |
| 2012 | 0.28x | ₩8.62 Billion | ₩30.69 Billion | ▲ +45.4% |
| 2010 | 0.19x | ₩4.76 Billion | ₩24.67 Billion | — |